{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:33:43Z","timestamp":1792017223855,"version":"4.4.0"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,22]]},"DOI":"10.18632\/oncotarget.12576","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T05:27:42Z","timestamp":1476250062000},"page":"76590-76603","source":"Crossref","is-referenced-by-count":16,"title":["Reduced PAK1 activity sensitizes FA\/BRCA-proficient breast cancer cells to PARP inhibition"],"prefix":"10.18632","volume":"7","author":[{"given":"Olga","family":"Villamar Cruz","sequence":"first","affiliation":[{"name":"UBIMED, Facultad de Estudios Superiores-Iztacala, UNAM, Tlalnepantla, Estado de M\u00e9xico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Y.","family":"Prudnikova","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Araiza-Olivera","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Perez-Plasencia","sequence":"additional","affiliation":[{"name":"UBIMED, Facultad de Estudios Superiores-Iztacala, UNAM, Tlalnepantla, Estado de M\u00e9xico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Johnson","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Bernhardy","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Slifker","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Renner","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chernoff","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Arias-Romero","sequence":"additional","affiliation":[{"name":"UBIMED, Facultad de Estudios Superiores-Iztacala, UNAM, Tlalnepantla, Estado de M\u00e9xico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.72.121801.161742","article-title":"Biology of the p21-activated kinases","volume":"7","author":"Bokoch","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"2","first-page":"97","article-title":"A tale of two Paks","volume":"10","author":"Chernoff","year":"2008","journal-title":"Biol Cell"},{"key":"3","first-page":"13","article-title":"PAK signalling during the development and progression of cancer","volume":"1","author":"Chernoff","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"4","first-page":"8887","article-title":"Synergistic activation of p21-activated kinase 1 by phosphatidylinositol 4,5-bisphosphate and Rho GTPases","volume":"28","author":"Peterson","year":"2013","journal-title":"The Journal of biological chemistry"},{"key":"5","first-page":"18130","article-title":"Nuclear localization and chromatin targets of p21-activated kinase 1","volume":"28","author":"Kumar","year":"2005","journal-title":"J Biol Chem"},{"key":"6","first-page":"4156","article-title":"Rac1 signaling modulates BCL-6-mediated repression of gene transcription","volume":"2","author":"Matos","year":"2009","journal-title":"Mol Cell Biol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.celrep.2012.11.018","article-title":"MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response","volume":"2","author":"Kumar","year":"2012","journal-title":"Cell Rep"},{"key":"8","doi-asserted-by":"crossref","first-page":"e66585","DOI":"10.1371\/journal.pone.0066585","article-title":"Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"key":"9","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"2","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"10","first-page":"913","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"43","author":"Helleday","year":"2005","journal-title":"Nature"},{"key":"11","first-page":"917","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"43","author":"Ashworth","year":"2005","journal-title":"Nature"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Li, Yu. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene. 2014.","DOI":"10.1038\/onc.2014.295"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Arun, Akar, Gutierrez-Barrera, Hortobagyi, Ozpolat. The PARP inhibitor AZD2281 (Olaparib) induces autophagy\/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol. 2015.","DOI":"10.3892\/ijo.2015.3003"},{"key":"14","first-page":"3671","article-title":"Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial cells","volume":"7","author":"Chernoff","year":"2013","journal-title":"Cancer Res"},{"key":"15","first-page":"914","article-title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studydagger","volume":"2","author":"Poveda","year":"2015","journal-title":"Ann Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11912-999-0002-x","article-title":"Assessing the role of platinum agents in aggressive breast cancers","volume":"1","author":"Sikov","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Yellapu, Pulaganti, Babu. Bioinformatics Exploration of PAK1 (P21-activated kinase-1) Revealed Potential Network Gene Elements in Breast Invasive Carcinoma. J Biomol Struct Dyn. 2016; pp. 1\u201327.","DOI":"10.1080\/07391102.2016.1216894"},{"key":"18","first-page":"23899","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin","volume":"27","author":"Bishop","year":"2000","journal-title":"J Biol Chem"},{"key":"19","first-page":"9446","article-title":"Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth","volume":"10","author":"Marakovits","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","first-page":"123","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"36","author":"de Bono","year":"2009","journal-title":"N Engl J Med"},{"key":"21","first-page":"139","article-title":"Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer","volume":"7","author":"Ashworth","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"22","first-page":"1191","article-title":"A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"7","author":"Calvert","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"23","first-page":"5229","article-title":"Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer","volume":"5","author":"Mooi","year":"1992","journal-title":"Cancer research"},{"key":"24","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"34","author":"van der Velde","year":"2002","journal-title":"The New England journal of medicine"},{"key":"25","first-page":"1389","article-title":"Proto-oncogene amplification and human breast tumor phenotype","volume":"4","author":"Theillet","year":"1989","journal-title":"Oncogene"},{"key":"26","first-page":"R81","article-title":"Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer","volume":"1","author":"Landberg","year":"2008","journal-title":"Breast Cancer Res"},{"key":"27","first-page":"333","article-title":"The 11q13-q14 amplicon: clinicopathological correlations and potential drivers","volume":"5","author":"Reis-Filho","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"28","first-page":"314","article-title":"p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer","volume":"1","author":"Mattingly","year":"2008","journal-title":"Neoplasia"},{"key":"29","first-page":"5839","article-title":"A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells","volume":"2","author":"Chernoff","year":"2010","journal-title":"Oncogene"},{"key":"30","first-page":"1422","article-title":"p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells","volume":"27","author":"Kumar","year":"2004","journal-title":"J Biol Chem"},{"key":"31","first-page":"7177","article-title":"Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells","volume":"10","author":"Hoeflich","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","first-page":"3397","article-title":"PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling","volume":"3","author":"Hahn","year":"2012","journal-title":"Oncogene"},{"key":"33","doi-asserted-by":"crossref","first-page":"e22911","DOI":"10.1371\/journal.pone.0022911","article-title":"Fanconi anemia core complex gene promoters harbor conserved transcription regulatory elements","volume":"6","author":"Schindler","year":"2011","journal-title":"PLoS One"},{"key":"34","first-page":"3700","article-title":"alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini","volume":"12","author":"Weaver","year":"2007","journal-title":"J Cell Sci"},{"key":"35","first-page":"455","article-title":"Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis","volume":"3","author":"Rayala","year":"2015","journal-title":"Oncogene"},{"key":"36","first-page":"12035","article-title":"Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma","volume":"1","author":"Zhang","year":"2015","journal-title":"Int J Mol Sci"},{"key":"37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ncb0901-785","article-title":"ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini","volume":"3","author":"Brugge","year":"2001","journal-title":"Nat Cell Biol"},{"key":"38","first-page":"402","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"2","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"39","first-page":"27","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"2","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T13:31:19Z","timestamp":1597671079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":39,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2016,11,22]]}},"alternative-id":["12576","27740936"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12576","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}